Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: At the crossroads? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 7, 2006

    Pharma: At the crossroads?

    The steep correction in May and June 2006 had seen the Sensex reach its lowest ebb since the start of the year. Since then, while the BSE-Sensex has considerably recovered to reach the magical 13,000 mark, what is interesting to note is that many stocks have not reached the levels that they had before the correction. In this rally, banking and IT stocks have been the 'apple of investors' eye'. In comparison, pharma stocks have not really set the pulse racing. Here, we shall find out, which of the pharma stocks under our coverage have garnered investor interest and the reasons for the same.

    Company Price on
    Oct 31, 2006 (Rs)
    Price on
    June 14, 2006 (Rs)
    BSE Sensex 12,962 8,929 45.2%
    Nicholas Piramal 237 158 50.3%
    Cipla 262 192 36.5%
    Sun Pharma 905 687 31.7%
    Dr.Reddy's 748 582 28.5%
    Pfizer 854 687 24.3%
    GSK Pharma 1,149 945 21.7%
    Wockhardt 390 336 16.3%
    Ranbaxy 400 348 15.0%
    Novartis 431 390 10.4%
    Aventis 1,542 1,430 7.8%
    Biocon 365 341 6.9%

    Nicholas Piramal: Nicholas Piramal has been the highest gainer in the pharma universe under our coverage having notched gains of around 50% since its low on June 14 2006. The optimism with regards to the stock can be attributed to increasing contribution from its custom manufacturing business (with global innovator companies) to total revenues. Nicholas' strategy involves partnering with global pharma majors to drive its custom pharma sales rather than focus on generics. The company has been active on the acquisition front too. Besides the Avecia acquisition in December 2005, Nicholas Piramal acquired Pfizer's Morpeth facility in the UK to further bolster its custom manufacturing revenues.

    Cipla: In the generics space, Cipla has been a rewarding story for investors due to its low risk strategy of supplying bulk drugs to global generic companies. Of late, this business model has assumed importance given the highly competitive nature of the generics markets in the US and Europe. The icing on the cake for Cipla was the 180-day exclusivity granted to Teva for the two drugs 'Proscar' and 'Zoloft'. Since Cipla is the supplier to the Teva/Ivax combine, the company was able to capitalise on this opportunity to augment its revenues. Besides this, the company has been delivering consistent results over the last few quarters, which has also aided the buoyancy in the stock.

    Sun Pharma: Despite directly competing in the highly competitive US generics market (through its subsidiary Caraco), Sun Pharma has still been able to report robust performances quarter over quarters, probably explaining why the stock has gained around 32% since reaching its lowest level during the year. The company has been relatively conservative in charting its growth path in comparison to its more aggressive peers Ranbaxy and Dr. Reddy's and this strategy seems to have reaped benefits. The company's focus on speciality and niche product segments have entrenched its hold over the domestic market and is expected to stand the company in good stead in the regulated markets as well.

    Pfizer: Pfizer has been the top gainer amongst the MNC pharma stocks, having notched returns of 24% since June. Amongst its MNC peers, the company was more aggressive this year in terms of product introductions, having introduced 3 new products from its parent's folio. Besides this, the company's restructuring efforts in terms of aligning the product portfolio in line with its parent and improving field force productivity has been reflected in its performance especially on the operating margin front. That said, given the fact that the global parent, Pfizer Inc., has divested its consumer healthcare business, the impact of the same on the Indian operations will be the key development to watch out for.

    To sum up....
    Looking ahead, while generics, contract research and manufacturing (CRAMS) are expected to be the way forward for domestic pharma companies, launch of patented products from the parents' product stable in the post patent era will be critical growth drivers for MNC pharma companies. However, the going may not be that easy. In the case of the former, competition and the consequent drop in prices, authorised generics and patent settlements have changed the dynamics of the global generics industry. As a result, only those players with scale, geographical reach, marketing and distribution network and a balanced product basket comprising of niche and plain vanilla generics will have the edge. For MNC pharma players, launch of patented products may not be that simple chiefly in terms of pricing of these products. Given the fact that the government intends to make medicines affordable to the public, prices of patented products are most likely to be subject to negotiations.

    In such a scenario, while we are positive on the growth prospects of the pharma industry in the long-term (growth is visible amongst most of the pharma companies under our coverage), investors, nevertheless, need to give due consideration to valuations and adopt a stock specific strategy while investing in the sector.



    Equitymaster requests your view! Post a comment on "Pharma: At the crossroads?". Click here!


    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working (Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    The Key Factor Pushing Gold Up These Days (Outside View)

    Aug 21, 2017

    PersonalFN explains the chief factor pushing gold prices up of late.

    How Unique Are the Companies You Invest In? (The 5 Minute Wrapup)

    Aug 21, 2017

    One of the hallmarks of successful investing is to look out for companies that have a unique and enduring moat.

    You've Heard of Timeless Books... Ever Heard of Timeless Stocks? (The 5 Minute Wrapup)

    Aug 19, 2017

    Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 (Close)